IP Library Granted Patent US 8,716,235
Granted Patent B2
US 8,716,235 · App. 13/860,109 · Granted May 6, 2014

Method for inhibiting metastasis by using anti-CCL3 antibodies

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,716,235
App. No.
13/860,109
Granted
May 6, 2014
Kind
B2
Abstract

Methods and compositions are provided for inhibiting metastasis of a tumor in a subject, or of inhibiting progression of a primary tumor in a subject which requires macrophages for progression.

Claims (7)

1. A method of inhibiting metastasis in a subject of a primary tumor which requires macrophages for progression, comprising administering to the subject an amount of an inhibitor of CCL3 activation of macrophages effective to inhibit metastasis of a tumor wherein the inhibitor of CCL3 activation of macrophages is a neutralizing antibody or a fragment of such an antibody.

2. The method of claim 1 , wherein the tumor is a tumor of the breast, nasopharynx, pharynx, lung, bone, brain, sialaden, stomach, esophagus, testes, ovary, uterus, endometrium, liver, small intestine, appendix, colon, rectum, gall bladder, pancreas, kidney, urinary bladder, breast, cervix, vagina, vulva, prostate, thyroid or skin or is a glioma.

3. The method of claim 1 , wherein the tumor is a tumor of the breast, endometrium or prostate or wherein the primary tumor is a brain tumor or glioma.

4. The method of claim 1 , wherein metastasis is inhibited in lung, bone and/or brain tissue.

5. The method of claim 1 , wherein the antibody is a human antibody, a humanized antibody or a chimeric antibody or wherein the fragment is of a human antibody, of a humanized antibody or of a chimeric antibody.

6. The method of claim 1 , wherein the CCL3 is metastasis-associated-macrophage-secreted CCL3.

7. The method of claim 1 , further comprising administering to the subject an amount of an antagonist of a CCR5 receptor or an antagonist of a CCR1 receptor.

Assignments (5)
MERGER AND CHANGE OF NAME Recorded Feb 26, 2019
From: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.; ALBERT EINSTEIN COLLEGE OF MEDICINE
To: ALBERT EINSTEIN COLLEGE OF MEDICINE
Reel/Frame 048438/0275 →
CORRECTIVE ASSIGNMENT TO CORRECT PATENT NO. 8726046 TO 8729046 PREVIOUSLY RECORDED AT REEL: 036876 FRAME: 0018. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Oct 28, 2015
From: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY
To: COM AFFILIATION, INC.
Reel/Frame 036984/0184 →
CHANGE OF NAME Recorded Oct 20, 2015
From: COM AFFILIATION, INC.
To: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Reel/Frame 036907/0795 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 16, 2015
From: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY
To: COM AFFILIATION, INC.
Reel/Frame 036876/0018 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2013
From: POLLARD, JEFFREY W.
To: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY
Reel/Frame 030335/0260 →